Search
Trofinetide
go.drugbank.com/drugs/DB06045ApprovedTrofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was appro...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsTapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalTapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as ...
Categories: Aryl Hydrocarbon Receptor Agonist, Cytochrome P-450 SubstratesCenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigationalCenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersAtrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Endothelin Receptor Antagonists, Endothelin A Receptor AntagonistsAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes ...
Mixtures: INCRESINA PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalIt is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalEltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesNalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawnNalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist. … [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin help...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesArmodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalArmodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 Inducers